Coherus Biosciences | CHRS - Current Liabilities


Coherus Biosciences reported $75.51M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
AbbVie USD 43.1B 1.46B Sep/2026
Acadia Pharmaceuticals USD 332.22M 29.22M Sep/2026
Akebia Therapeutics USD 162.35M 1.48M Sep/2026
ALKERMES USD 651.93M 10.16M Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Amarin USD 175.14M 10.94M Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
Baxter International USD 3.81B 218M Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Coherus Biosciences USD 75.51M 56.82M Jun/2026
Eli Lilly USD 47B 745M Sep/2026
Fujifilm JPY 1.35T 95.27B Sep/2026
Gilead Sciences USD 12B 982M Sep/2026
Ironwood Pharmaceuticals USD 34.73M 1.88M Sep/2026
Merck USD 28.8B 1.07B Sep/2026
Myriad Genetics USD 130.7M 500K Jun/2026
Pacira USD 126.1M 4.08M Sep/2026
Perrigo USD 1.02B 34.4M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
PTC Therapeutics USD 776.08M 5.01M Sep/2026
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
Teva Pharmaceutical Industries USD 15.42B 221M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026
Xencor USD 76.27M 5.6M Sep/2026
Zoetis USD 2.68B 621M Sep/2026